Just a moment…

Just a moment… Enable JavaScript and Cookies to continue This request seems a bit unusual, so we need to confirm that you are human. Please press the button until it becomes completely green. Thank you for your cooperation! Press and hold Press and hold the button If you think this is an error, please contact…

Read More

AstraZeneca stock jumps after surprise lung disease trial win

AstraZeneca‘s stock rose over 3% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift…

Read More